MIPI Molecular Insight Pharmaceuticals, Inc. featured news, full reports, and detailed charts
Molecular Insight Pharmaceuticals, Inc. (MIPI) Wrap Up:
In this annual report on Form 10-K, unless the context indicates otherwise, references to “Molecular Insight,” “the Company,” “our company,” “we,” “us,” and similar references, refer to Molecular Insight Pharmaceuticals, Inc. All references to years in this Form 10-K, unless otherwise noted, refer to our fiscal years, which end on December 31. For example, a reference to “2007” or “fiscal 2007” means the 12-month period that ended December 31, 2007. Overview We are a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet medical needs. We are focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f04%2f01%2f0000950135-08-002206.html#FIS_BUSINESS"Molecular Insight Pharmaceuticals, Inc. (MIPI:NASDAQ)
Snapshot of Molecular Insight Pharmaceuticals, Inc. (MIPI)
|
OPEN
--
|
PREVIOUS CLOSE
$4.19
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
06/17/09 - $7.90
|
52 WEEK LOW
03/9/09 - $1.15
|
|
|
MARKET CAP
105.9M
|
AVERAGE VOLUME 3 mo
35.5K
|
|
|
DILUTED EPS TTM
$-2.75
|
SHARES OUTSTANDING
25.3M
|
|
|
MIPI Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
MIPI Top Compensated Officers
Executives, Board Directors
Key developments for Molecular Insight Pharmaceuticals, Inc. (MIPI)
To present an overview of the company and its pipeline of targeted therapeutic oncology radiopharmaceuticals
Molecular Insight Pharmaceuticals, Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009. For the third quarter of 2009, the company reported a net loss of $21.4 million or $0.85 per basic and diluted share on total revenue of $62,000 compared to a net loss of $24.7 million or $0.99 per basic and diluted share on total revenue of $101,000 in the third quarter of 2008. Loss from operations for the period was $16.31 million compared to $19.75 million for the same period previous year. For the nine months, the company reported a net loss of $53.3 million or $2.12 per basic and diluted share on total revenue of $238,000 compared to net loss of $65.4 million or $2.62 per basic and diluted share on total revenue of $450,000 in the first nine months of 2008. Loss from operations for the period was $38.17 million compared to $51.23 million for the same period previous year. Net cash burn for the period was $45 million compared to $34 million for the same period previous year.
Molecular Insight Pharmaceuticals, Inc. expected to Report Fiscal Year 2009 Results on March 15, 2010. This event was calculated by Capital IQ (Created on November 9, 2009).
MIPI Competitors
| Company | Last | Change | |
| No competitor information is available for MIPI. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | MIPI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 162.9x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
MIPI |
||
MIPI transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||